Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.
The last earnings update was 36 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Navidea Biopharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Navidea Biopharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Navidea Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Navidea Biopharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Navidea Biopharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Navidea Biopharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Navidea Biopharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Navidea Biopharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Navidea Biopharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Navidea Biopharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Navidea Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Navidea Biopharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Navidea Biopharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 17.7x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Jed A. Latkin is Chief Executive Officer of Navidea Biopharmaceuticals, Inc. since October 1, 2018. He has been Chief Financial Officer, Chief Operating Officer, Treasurer and Secretary of Navidea Biopharmaceuticals, Inc. since April 21, 2016 and serves as its Principal Accounting Officer. He was Interim Chief Executive Officer of Navidea Biopharmaceuticals, Inc. since August 14, 2018 until October 1, 2018. He is Director of Navidea Biopharmaceuticals, Inc. since August 14, 2018. Mr. Latkin has been responsible for a large diversified portfolio of asset based investments in varying industries including product manufacturing, agriculture, energy and healthcare. Mr. Latkin has served as Chief Financial Officer of Viper Powersports, Inc., Chief Executive Officer of End of Life Petroleum Holdings, LLC, Chief Executive Officer of Black Elk Energy, LLC, Portfolio Manager of Precious Capital, LLC and Chief Financial Officer of West Ventures, LLC. He served as Principal Executive Officer of Navidea Biopharmaceuticals, Inc. from May 17, 2016 to September 22, 2016. Prior to his position at Nagel Avenue Capital, LLC, he was a Senior Research Analyst, Global Markets for ING Investment Management and held various finance roles at Troika Dialog, Morgan Stanley, Fleet Boston Robertson Stephens and Citicorp Securities. Mr. Latkin served as Portfolio Manager of Asset Based Lending of Platinum Partners Value Arbitrage Fund L.P. since 2010 and was responsible for a large diversified portfolio of asset based investments in varying industries including product manufacturing, agriculture, energy, healthcare and consumer discretionary. Mr. Latkin has more than 20 years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals by providing executive direction and preserving operational control during transitional periods. Mr. Latkin was employed at Nagel Avenue Capital, LLC since 2010. He serves on the boards of the Renewable Fuels Association and Buffalo Lake Advanced Biofuels. He served as a Director of Viper Powersports Inc. from August 23, 2012 to March 6, 2013. Mr. Latkin has a BA from Rutgers University and an MBA from Columbia Business School.
Jed's compensation has been consistent with company performance over the past year.
Jed's remuneration is higher than average for companies of similar size in Germany.
Chief Medical Officer
Director of Finance & Administration
Chief Compliance Officer
Senior Director of Corporate Communications
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Navidea Biopharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
Member of Scientific Advisory Board
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Navidea Biopharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.